Immutep updates market on TACTI-004 and pipeline priorities
Posted on March 19th, 2026
Immutep (ASX: IMM) (NASDAQ : IMMP) CEO & Executive Director Marc Voigt discusses the TACTI-004 trial update and outlines the company’s next steps, including a detailed data review and strategic planning. He also highlights ongoing progress across the pipeline, with multiple programs advancing and further clinical milestones expected.
Addition/changes to Adviser Resources Centre (ARC)
Please note the following additions/changes to the ARC. Please take time to view all changes at your earliest convenience and destroy previous versions of these documents.
